Otonomy’s Otividex Fails Again In Phase III Meniere’s Study

 
• By Joseph Haas

Otividex did not significantly reduce vertigo three months after treatment, so Otonomy appears to be moving on from Meniere’s disease and focusing on earlier-stage tinnitus and hearing loss candidates.

Woman with hands on head, feeling headache, dizzy sense of spinning dizziness, a problem with the inner ear, brain, or sensory nerve pathway.
Otonomy hoped to produce a therapy for the vertigo caused by Meniere's

More from Clinical Trials

More from R&D